If You Invested in Global Cord Bloo (CORBF)

Global Cord Blood Corporation (CORBF) is a company that has been the subject of court-supervised provisional liquidation proceedings in the Cayman Islands. According to a current report on Form 6-K filed under the Securities Exchange Act of 1934, the Grand Court of the Cayman Islands issued an order on September 22, 2022 appointing joint provisional liquidators for Global Cord Blood Corporation pursuant to Section 104(2) of the Companies Act of the Cayman Islands.

The company is identified in regulatory filings under the name Global Cord Blood Corporation, and the filing describes it as a foreign private issuer that reports under Form 20-F. The Form 6-K notes that joint provisional liquidators from Grant Thornton entities were appointed by the Court to oversee matters relating to the company’s provisional liquidation.

Provisional liquidation and court supervision

The appointment of joint provisional liquidators, often referred to as JPLs, indicates that Global Cord Blood Corporation is subject to a formal restructuring or winding-up process under the supervision of the Grand Court of the Cayman Islands. The JPLs act under the authority of the Court order and provide periodic reports to the Court on the status of the company and the provisional liquidation proceedings.

In the Form 6-K, Global Cord Blood Corporation reports that the JPLs have prepared and furnished multiple reports to the Court over time. These reports are numbered sequentially and provide updates on the provisional liquidation. The filing specifically references a Fourteenth Report prepared by the JPLs.

JPLs’ Fourteenth Report

According to the Form 6-K, on December 1, 2025 the joint provisional liquidators furnished their Fourteenth Report to the Grand Court of the Cayman Islands. The company states that a copy of this Fourteenth Report is available through its investor relations materials and through a creditor update page maintained by Grant Thornton. The filing also notes that previous reports by the JPLs were furnished on a series of dates over several years.

Historical reporting by the JPLs

The Form 6-K includes a table listing dates on which earlier reports by the joint provisional liquidators were furnished. These dates span multiple years and show that the provisional liquidation process has involved regular reporting to the Court, with reports furnished in October and December of 2022, several dates in 2023, and multiple dates in 2024 and 2025. This pattern of reporting reflects an extended period of court-supervised oversight of Global Cord Blood Corporation.

Regulatory reporting framework

In the same Form 6-K, Global Cord Blood Corporation indicates that it files annual reports under Form 20-F rather than Form 40-F, confirming its status as a foreign private issuer for U.S. securities law purposes. The 6-K itself is furnished pursuant to Rules 13a-16 or 15d-16 under the Securities Exchange Act of 1934, which govern current reports by foreign private issuers.

Because the available information is focused on the provisional liquidation process and related court reports, public investors researching CORBF will primarily find regulatory and court-related disclosures rather than details about ongoing commercial operations. The presence of joint provisional liquidators and repeated reports to the Grand Court of the Cayman Islands indicate that Global Cord Blood Corporation is in a formal restructuring or winding-up context under Cayman Islands law.

Key points about Global Cord Blood Corporation

• Global Cord Blood Corporation is identified as a foreign private issuer that reports on Form 20-F.
• The Grand Court of the Cayman Islands appointed joint provisional liquidators for the company on September 22, 2022 under Section 104(2) of the Companies Act of the Cayman Islands.
• The joint provisional liquidators have furnished multiple reports to the Court, including a Fourteenth Report dated December 1, 2025.
• The company has used Form 6-K to furnish information about these reports and the status of the provisional liquidation.

Investor considerations

Based on the Form 6-K disclosure, Global Cord Blood Corporation is subject to an ongoing provisional liquidation process in the Cayman Islands. For investors and researchers, the most relevant information about CORBF is found in court-related reports prepared by the joint provisional liquidators and in the company’s Exchange Act filings, including Form 6-K and Form 20-F. These documents describe the legal and procedural status of the company under Cayman Islands and U.S. securities law.

Anyone evaluating CORBF should recognize that the presence of joint provisional liquidators and repeated reporting to the Grand Court of the Cayman Islands indicate that Global Cord Blood Corporation is not in a standard operating situation. Instead, the company is under court supervision, and the JPLs’ reports provide insight into the progress and status of the provisional liquidation.